Company news
Lionco Pharmaceutical Group Co., Ltd. Class A (SSE:603669) news
Lionco Pharmaceutical Group Co., Ltd. Class A news releases on 6ix. Latest, Sep 30, 2026: "Lionco Pharmaceutical Group Co., Ltd."Announcement on Obtaining…
Press releases & updates
"Lionco Pharmaceutical Group Co., Ltd."Announcement on Obtaining Drug Registration Certificate for Isavuconazonium Sulfate for Injection by Wholly-owned Subsidiary
September 29, 2026
"Lionco Pharmaceutical Group Co., Ltd."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
September 16, 2026
"Lionco Pharmaceutical Group Co., Ltd."Announcement on Resolutions of the 12th Meeting of the 5th Board of Directors
August 31, 2026
"Lionco Pharmaceutical Group Co., Ltd."Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026
August 14, 2026
"Lionco Pharmaceutical Group Co., Ltd."Announcement on Selection of the Subsidiary's Product Huperzine A for Injection in the Inter-Provincial Alliance Centralized Procurement
August 12, 2026
"Lionco Pharmaceutical Group Co., Ltd."Indicative Announcement on "Lionco Convertible Bonds" Expected to Meet Conditions for Revising Conversion Price
August 3, 2026
"Lionco Pharmaceutical Group Co., Ltd."Announcement on Abnormal Fluctuations in Stock Trading
July 20, 2026
"Lionco Pharmaceutical Group Co., Ltd."Semi-annual Performance Forecast for 2026
July 14, 2026
"Lionco Pharmaceutical Group Co., Ltd."Announcement on Conversion Result of Convertible Bonds and Share Changes
July 2, 2026
Announcement on Follow-up Rating Results of "Lionco Convertible Bonds" in 2026
June 26, 2026
Announcement on No Downward Revision of Conversion Price of "Lionco Convertible Bonds"
June 16, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
June 12, 2026
Announcement on Resignation of Secretary of the Board of Directors and Deputy General Manager
June 10, 2026
Announcement on Early Return of Raised Funds Temporarily Used to Supplement Current Capital
June 9, 2026
Indicative Announcement on Expected Satisfaction of Conversion Price Correction Conditions for ""Lionco Convertible Bonds"
May 19, 2026
Announcement on the Company's and Its Wholly-owned Subsidiaries' Application for Comprehensive Credit Line from Banks in 2026 and Providing Corresponding Guarantee
April 28, 2026
Announcement on Postponing Disclosure of 2025 Annual Report and Report for Q1 2026
April 24, 2026
Announcement on Cancellation of Repurchased Shares Without Adjustment of Conversion Price for Convertible Bonds
April 21, 2026
Announcement on Conversion Result of Convertible Bonds and Share Changes
April 3, 2026
Announcement on the Reply to the Inquiry Letter Regarding Matters Relating to the Earnings Forecast of Lionco Pharmaceutical Group Co., Ltd.
March 24, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
March 5, 2026
Announcement on Changing Signatory Certified Public Accountant
March 2, 2026
Announcement on Release of Pledge of Partial Shares of Controlling Shareholders
February 11, 2026
Announcement on Resolutions of the 6th Meeting of the 5th Board of Directors
January 30, 2026
Earnings Preannouncement for 2025
January 23, 2026
Announcement on ""Corporate Value and Return Enhancement"" Action Plan
December 30, 2025
Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025
December 24, 2025
Announcement on No Downward Revision of Conversion Price of ""Lionco Convertible Bonds"
December 9, 2025
Announcement on Engagement of Audit Institution for 2025
December 2, 2025
Announcement on Interest Payment for Corporate Convertible Bonds
November 24, 2025
Announcement on Handling of Pledge of Partial Shares of Controlling Shareholder
November 14, 2025
Report for Q3 2025
October 30, 2025
Announcement on Subsidiary’s Prospective Winning in the National Centralized Drug Procurement
October 29, 2025
Announcement on Resolutions of the 1st Meeting of the 5th Board of Directors
October 10, 2025
Announcement on Resolutions of the 21st Meeting of the 4th Board of Supervisors
September 22, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
September 19, 2025
Announcement on Resolutions of the 20th Meeting of the 4th Board of Supervisors
August 22, 2025
Announcement on No Downward Revision of Conversion Price of "Lionco Convertible Bonds" and Suspension and Resumption of Conversion
July 30, 2025
Semi-annual Earnings Preannouncement for 2025
July 14, 2025
Indicative Announcement on Expected Satisfaction of Conversion Price Correction Conditions for "Lionco Convertible Bonds"
July 7, 2025
Announcement on Convening the 2024 Annual and Q1 2025 Performance Briefing
June 18, 2025
Announcement on Follow-up Rating Results of "Lionco Convertible Bonds" in 2025
June 17, 2025
Announcement on Early Return of Raised Funds for Temporary Supplement to Current Capital
June 16, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 23, 2025
Announcement on Obtaining Notice of Approval for Drug Clinical Trials by Wholly-owned Subsidiary
April 28, 2025
Report for Q1 2025
April 25, 2025
Announcement on the Company's and Its Wholly-owned Subsidiaries' Application for Comprehensive Credit Line from Banks in 2025 and Providing Corresponding Guarantee
April 18, 2025
Announcement on Subsidiary's Vecuronium Bromide for Injection Passing Generic Drug Consistency Evaluation
April 11, 2025
Announcement on the Optional Reselling Results of "Lionco Convertible Bonds"
April 10, 2025
The 9th Indicative Announcement on Optional Sell-back of "Lionco Convertible Bonds"
April 7, 2025